Relapsing Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-07-19FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)
FDA approved a supplemental application for COPAXONE (glatiramer acetate) by Teva Neuroscience, Inc.
-
CLINICAL_TRIALS trial_result · 2019-01-09Clinical Trial Update: A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis [Phase 3]
Phase 3 trial of daily oral laquinimod 0.6 mg in relapsing multiple sclerosis terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2019-01-08Clinical Trial Update: A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course [Phase 3]
Phase 3 trial update evaluating long-term safety, tolerability, and effect on disease course for Relapsing Multiple Sclerosis; study termina…
-
CLINICAL_TRIALS trial_result · 2018-03-30Clinical Trial Update: Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ [Phase 4]
A Phase 4 trial evaluated Rebif (interferon beta-1a) delivered via the RebiSmart device for effectiveness in Clinically Isolated Syndrome an…
-
CLINICAL_TRIALS trial_result · 2018-03-27Clinical Trial Update: Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS [Phase 1]
Phase 1 pharmacokinetics and pharmacodynamics study of RPC1063 in relapsing multiple sclerosis to characterize absorption, exposure, and pha…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-01-16Clinical Trial Update: Plasma Exchanges in Multiple Sclerosis (MS) Relapses [Phase 3]
Phase 3 clinical trial update on plasma exchanges for relapses in multiple sclerosis; study completed.
-
CLINICAL_TRIALS trial_result · 2017-07-18Clinical Trial Update: A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis [Phase 3]
Phase 3 clinical trial comparing ocrelizumab to interferon beta-1a in relapsing multiple sclerosis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-07-18Clinical Trial Update: A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis [Phase 3]
A Phase 3 trial comparing ocrelizumab with interferon beta-1a in relapsing multiple sclerosis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-06-05Clinical Trial Update: Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies [Phase 4]
A Phase 4 trial evaluated switching to natalizumab in participants with relapsing multiple sclerosis after failure on other therapies; the s…
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients [Phase 3]
Phase 3 trial update reports tolerability, safety, and health outcomes in relapsing multiple sclerosis and notes completion of the study.
-
CLINICAL_TRIALS trial_result · 2017-01-25Clinical Trial Update: Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017) [Phase 3]
Phase 3 trial update examining flu-like symptoms in relapsing multiple sclerosis patients switching from non-pegylated interferon beta thera…
-
CLINICAL_TRIALS trial_result · 2017-01-13Clinical Trial Update: Long-Term Safety and Efficacy Study of Peginterferon Beta-1a [Phase 3]
Phase 3 long-term safety and efficacy study of peginterferon beta-1a in relapsing multiple sclerosis completed, with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2016-09-29Clinical Trial Update: JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
Clinical trial update describing a completed study that evaluates JC virus antibody status in participants with relapsing multiple sclerosis…
-
CLINICAL_TRIALS trial_result · 2016-05-24Clinical Trial Update: A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS) [Phase 2]
This update reports results from a Phase 2 study of atacicept in relapsing multiple sclerosis (ATAMS). The trial was terminated and results …
-
CLINICAL_TRIALS trial_result · 2016-05-24Clinical Trial Update: Atacicept in Multiple Sclerosis Extension Study, Phase II [Phase 2]
Phase II extension study of atacicept in relapsing multiple sclerosis was terminated. Results were posted in 2016.
-
CLINICAL_TRIALS trial_result · 2015-05-29Clinical Trial Update: Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients
This clinical trial update assesses the impact of disease-modifying therapies and associated support services on patients with Relapsing Mul…
-
CLINICAL_TRIALS withdrawal · 2014-11-17Clinical Trial Update: Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy [Phase 4]
Phase 4 trial evaluating transition from subcutaneous interferon therapy to peginterferon beta-1a (BIIB017) in relapsing multiple sclerosis …
-
CLINICAL_TRIALS trial_result · 2014-09-19Clinical Trial Update: Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis [Phase 3]
A Phase 3 trial evaluating the efficacy and safety of peginterferon beta-1a in relapsing multiple sclerosis has completed and results have b…
-
CLINICAL_TRIALS trial_result · 2014-05-22Clinical Trial Update: Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta [Phase 3]
A Phase 3 trial evaluated the efficacy and safety of teriflunomide in relapsing multiple sclerosis patients treated with interferon-beta; th…
-
FDA approval · 2014-04-30FDA Approved: GILENYA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for GILENYA (fingolimod HCl) from Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2014-03-10Clinical Trial Update: The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial [Phase 4]
Phase 4 trial comparing REBIF (interferon beta-1a) with Glatiramer Acetate in relapsing multiple sclerosis. Results were posted in 2014 and …
-
CLINICAL_TRIALS trial_result · 2014-02-04Clinical Trial Update: An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device
This completed observational retrospective audit in the UK & Ireland evaluated patient adherence to Rebif injections when using the RebiSmar…
-
CLINICAL_TRIALS withdrawal · 2013-08-27Clinical Trial Update: A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability [Phase 2]
A multinational Phase 2 randomized, double-blind, placebo-controlled study assessing safety and tolerability in relapsing multiple sclerosis…
-
CLINICAL_TRIALS trial_result · 2012-06-19Clinical Trial Update: Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS) [Phase 3]
Phase 3 study evaluating the effect of fingolimod on immune responses to seasonal influenza vaccination and tetanus booster in relapsing mul…
-
CLINICAL_TRIALS trial_result · 2011-11-10Clinical Trial Update: Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study [Phase 2]
A Phase 2 safety study of Trichuris suis ova therapy for relapsing multiple sclerosis has completed.